XOMA Royalty Corp.
NASDAQ:XOMABiotechnology
+$0.19 today
- Market cap
- $503.77M
- Beta
- 0.87
- P/E (TTM)
- 15.8
- EPS (TTM)
- $2.65
Volume 4.22M
Average 0.21M
XOMA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
XOMA Royalty Corp.NASDAQ: XOMA
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA grows, but more slowly than its trailing trend
Q1 FY2026 EBITDA of $8.72M rose 36.7% year over year, behind the +447.8% change in trailing-twelve-month EBITDA. Sequentially, it fell 13.4% from the prior quarter.
Context
- EBITDA amounted to 91.7% of revenue in FY2025, up 72.7 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 2 analysts of -$10.21M (-121.4%) for the fiscal year ending Dec 2026, a slowdown from the +981.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $8.72M-13.4% QoQ
- Last fiscal yearDec 2025
- $47.82M+981.8% YoY
- LTMMar 2026
- $50.16M+447.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +36.7% | -117.9% | -154.5 pp |
| 1 year | +981.8% | -121.4% | -1103.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 47.82M USD
- Year-over-year change
- +981.8%
- 4-year CAGR
- +30.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 47.82M | +981.8% |
| FY2024 | 2024-12-31 | (5.42M) | +76.0% |
| FY2023 | 2023-12-31 | (22.56M) | -33.9% |
| FY2022 | 2022-12-31 | (16.85M) | -202.0% |
| FY2021 | 2021-12-31 | 16.52M | — |
EBITDA vs competitors
How XOMA compares with its peers on the latest reported figures
- XOMA's LTM Mar 2026 EBITDA of $50.16M is the highest of the 10 companies compared; the peer median is -$99.13M.
- Its year-over-year change of +447.8% is the highest of 10, against a peer median of -19.0%.
- EBITDA amounts to 138.4% of revenue for XOMA, versus a peer median of 2801.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $50.16M | +447.8% | — | 138.4% | |
| LTM Mar 2026 | -$18.62M | +52.1% | — | — | |
| LTM Mar 2026 | -$35.03M | -30.1% | — | — | |
| LTM Mar 2026 | -$53.46M | -44.4% | — | — | |
| LTM Mar 2026 | -$69.09M | -24.3% | — | — | |
| LTM Mar 2026 | -$99.13M | -3.1% | — | 5352.8% | |
| LTM Mar 2026 | -$111.17M | -19.0% | — | — | |
| LTM Mar 2026 | -$190.1M | -38.9% | — | — | |
| LTM Mar 2026 | -$194.47M | +21.0% | — | — | |
| LTM Mar 2026 | -$230.8M | +3.4% | — | 249.3% | |
| Peer median (excluding XOMA) | -$99.13M | -19.0% | — | 2801.0% | |
Competitors are the stored peer set for XOMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 38.16M | 6.03M | 4.76M | 28.49M | 52.15M |
| Cost of Revenue | 171K | 274K | 143K | 206K | 2.96M |
| Gross Profit | 37.99M | 5.75M | 4.62M | 28.28M | 49.18M |
| Gross Margin | 99.6% | 95.5% | 97.0% | 99.3% | 94.3% |
| Research & Development | 171K | 153K | 143K | 2.88M | 1.71M |
| Selling, General & Admin | 20.46M | 23.19M | 27.18M | 34.48M | 36.09M |
| Operating Expenses | 20.46M | 23.17M | 46.46M | 68.26M | 37.79M |
| Depreciation & Amortization | 167K | 274K | 900K | 216K | 2.97M |
| EBITDA | 16.52M | (16.85M) | (22.56M) | (5.42M) | 47.82M |
| EBITDA Margin | 43.3% | -279.5% | -474.2% | -19.0% | 91.7% |
| Operating Income | 17.53M | (17.41M) | (41.85M) | (39.98M) | 11.38M |
| Operating Margin | 45.9% | -288.9% | -879.5% | -140.3% | 21.8% |
| Interest Income | 0 | 694K | 0 | 0 | 0 |
| Interest Expense | 461K | 0 | 569K | 13.84M | 13.03M |
| Other Income / Expenses | (1.64M) | 295K | 1.02M | 20.5M | 20.43M |
| Income Before Tax | 15.89M | (17.12M) | (40.83M) | (19.48M) | 31.82M |
| Pre-Tax Margin | 41.6% | -284.0% | -858.2% | -68.4% | 61.0% |
| Income Tax Expense | 91K | (15K) | 0 | (5.66M) | 103K |
| Net Income | 15.8M | (17.1M) | (40.83M) | (13.82M) | 31.71M |
| Net Margin | 41.4% | -283.8% | -858.2% | -48.5% | 60.8% |
| EPS (Basic) | 0.69 | (1.98) | (4.04) | (1.65) | 1.53 |
| EPS (Diluted) | 0.65 | (1.98) | (4.04) | (1.65) | 1.46 |
| Weighted Avg Shares | 11.29M | 11.41M | 11.47M | 11.7M | 17.98M |
| Weighted Avg Shares (Diluted) | 12.19M | 11.41M | 11.47M | 11.7M | 17.98M |
XOMA Royalty Corp.
NASDAQ:XOMA
Intrinsic Alpha fair value
Locked
Current Price
$40.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.